# FDA Grants Accelerated Approval to Trutakna (atacicept) for IgA Nephropathy

> fda · REPORTED · 2026-07-07

The FDA granted accelerated approval to Vera Therapeutics' Trutakna (atacicept-vymj) on July 7, 2026, for adults with primary IgA nephropathy at risk of disease progression, based on its ability to reduce proteinuria. The clearance positions Trutakna in a growing class of IgAN treatments and sets up a commercial battle with Otsuka's similar medication.

About Vera Therapeutics: Vera Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for serious immunological and kidney diseases, with Trutakna being a BLyS and APRIL blocker indicated for IgA nephropathy patients.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://www.biopharmadive.com/news/vera-fda-approve-trutakna-IgAN-kidney-disease-atacicept/824620/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.